PWM
IMMX icon

Palumbo Wealth Management’s Immix Biopharma IMMX Stock Holding History

Palumbo Wealth Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55,232
Closed -$503K – 241
2026
Q1 		$503K Buy
+55,232
New +$406K 0.12% 127

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Palumbo Wealth Management's IMMX Position: Q2 2026 in Review

Palumbo Wealth Management sold out of Immix Biopharma (IMMX) in Q2 2026, closing a stake of 55,232 shares — an estimated $503K sold.

Palumbo Wealth Management first reported a position in IMMX in Q1 2026 and held it in 1 quarter. The position peaked at $503K in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Palumbo Wealth Management reported no remaining Immix Biopharma position as of Q2 2026 after selling out during the quarter.
  • Palumbo Wealth Management sold 55,232 Immix Biopharma shares in Q2 2026, an estimated $503K.
  • Palumbo Wealth Management first reported a position in Immix Biopharma in Q1 2026 and held it in 1 quarter.
  • Palumbo Wealth Management's Immix Biopharma position peaked at $503K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.